BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of BioHarvest Sciences in a note issued to investors on Tuesday, April 8th. HC Wainwright analyst A. Dayal anticipates that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences' Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.27) EPS, FY2026 earnings at $0.05 EPS, FY2027 earnings at $0.32 EPS and FY2028 earnings at $0.69 EPS.
Separately, Maxim Group assumed coverage on BioHarvest Sciences in a report on Wednesday, December 18th. They issued a "buy" rating and a $12.00 target price on the stock.
Check Out Our Latest Stock Report on BioHarvest Sciences
BioHarvest Sciences Stock Down 2.2 %
Shares of BioHarvest Sciences stock traded down $0.13 on Thursday, hitting $5.77. 85,554 shares of the company traded hands, compared to its average volume of 13,732. BioHarvest Sciences has a 52 week low of $5.45 and a 52 week high of $7.38. The company's 50-day moving average price is $5.74. The firm has a market cap of $94.77 million, a PE ratio of -4.62 and a beta of 0.84.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.05). The business had revenue of $7.17 million for the quarter, compared to analyst estimates of $7.24 million.
Institutional Trading of BioHarvest Sciences
An institutional investor recently bought a new position in BioHarvest Sciences stock. TD Waterhouse Canada Inc. bought a new position in BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 12,042 shares of the company's stock, valued at approximately $69,000. TD Waterhouse Canada Inc. owned 0.07% of BioHarvest Sciences as of its most recent filing with the SEC.
BioHarvest Sciences Company Profile
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
See Also
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
